Low impact
Gilead Sciences and Merck announced an experimental long-acting HIV combination pill met primary efficacy goals in late-stage clinical trials.
BLOOMBERG06/09, 05:01 AM
Related assets
Coming up for GILD
Explore next
Latest GILD news
Jin1008/14, 09:47 PM
FirstSquawk08/05, 03:08 AM
FirstSquawk08/05, 03:08 AM